Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center

Baykan, Betul; Sirin, Nermin Gorkem

Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center

Nermin Görkem ŞİRİN, (İstanbul Üniversitesi İstanbul Tıp Fakültesi, Nöroloji Anabilim Dalı, İstanbul. Türkiye)

Betül BAYKAN (İstanbul Üniversitesi İstanbul Tıp Fakültesi, Nöroloji Anabilim Dalı, İstanbul, Türkiye)

Epilepsi

1 0

Yıl: 2020 Cilt: 26 Sayı: 3 Sayfa Aralığı: 155 - 160 Metin Dili: İngilizce İndeks Tarihi: 17-02-2022

Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center

Öz:

Objectives: This retrospective study aimed to overview the efficacy and side effects of clobazam in patients with drug-resistant epilepsy who were followed in a tertiary epilepsy center. Methods: The patients who had been started clobazam as add-on therapy and have been followed for at least one year were recruited to participate in this study. The clinical, electrophysiologic and imaging features of the patients were reviewed. The side effects and efficacy of clobazam were noted. Results: Twelve patients with drug-resistant epilepsy who had focal epilepsy with structural etiology in nine, focal epilepsy with unknown etiology in one, combined focal and generalized epilepsy in one and epilepsy with myoclonic absences in one were included in this study. All patients had at least two antiepileptic drugs with moderate to high doses before clobazam therapy. The side effects were sedation, irritability and blurred vision in three patients. Two patients became seizure-free and seven patients had improved remarkably (≥50% seizure reduction). Only one patient discontinued the drug because of the side effects. Conclusion: Our results provide evidence in the efficacy of clobazam as add-on therapy in patients with drug-resistant epilepsy

Anahtar Kelime:

İlaç Tedavisine Dirençli Epilepsi Hastalarında Klobazam Ekleme Tedavisi: Üçüncü Basamak Epilepsi Merkezi Deneyimi

Öz:

Amaç: Bu geriye dönük çalışmanın amacı, üçüncü basamak epilepsi merkezinde ilaç tedavisine dirençli epilepsi hastalarında klobazam tedavisinin etkinliğini ve yan etkilerini araştırmaktır. Gereç ve Yöntem: Klobazamın ek tedavi olarak başlandığı ve tedavi başlandıktan sonra en az bir yıl boyunca takip edilen ilaç tedavisine dirençli hastalar çalışmaya dahil edildi. Hastaların klinik, elektrofizyolojik ve görüntüleme bulguları gözden geçirildi. Klobazam tedavisi sonrası ortaya çıkan yan etkiler ve nöbetler üzerine etkinlik değerlendirildi. Bulgular: On iki ilaç tedavisine dirençli epilepsi hastası çalışmaya dahil edildi. Hastaların dokuzu yapısal nedene bağlı fokal epilepsi, biri nedeni belirlenemeyen fokal epilepsi, biri kombine fokal ve jeneralize epilepsi ve biri miyoklonik absanslı epilepsi olgusu idi. Hastaların tümü klobazam tedavisi öncesi en az iki antiepileptik ilacı orta-yüksek dozlarda kullanıyordu. Yan etkiler üç hastada görüldü ve sedasyon, iritabilite ve bulanık görme olarak bildirildi. Klobazam tedavisi sonrası hastaların ikisi nöbetsizken, yedisi tedaviden belirgin olarak faydalandı (≥%50 nöbet azalması). Sadece bir hasta yan etkiler nedeniyle tedavi başlangıcından iki ay sonra ilacı bırakmak zorunda kaldı. Sonuç: Sonuçlarımız, ilaç tedavisine dirençli epilepsi hastalarında ek tedavi olarak klobazam’ın etkin olabileceğini göstermiştir

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512– 21.
2. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346(8968):140–4.
3. Odom N, Bateman LM. Sudden unexpected death in epilepsy, periictal physiology, and the SUDEP-7 Inventory. Epilepsia 2018;59(10):e157–e160.
4. Gastaut H, Low MD. Antiepileptic properties of clobazam, a 1-5 benzodiazepine, in man. Epilepsia 1979;20(4):437–46.
5. Allen JW, Oxley J, Robertson MM, Trimble MR, Richens A, Jawad SS. Clobazam as adjunctive treatment in refractory epilepsy. Br Med J (Clin Res Ed) 1983;286(6373):1246–7.
6. Arya R, Giridharan N, Anand V, Garg SK. Clobazam monotherapy for focal or generalized seizures. Cochrane Database Syst Rev 2018;7(7):CD009258.
7. Arya R, Anand V, Garg SK, Michael BD. Clobazam monotherapy for partial-onset or generalized-onset seizures. Cochrane Database Syst Rev 2014;(10):CD009258.
8. Bresnahan R, Martin-McGill KJ, Williamson J, Michael BD, Marson AG. Clobazam add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev 2019;10(10):CD004154.
9. Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci 1990;17(3):317–9.
10. Schmidt D, Rohde M, Wolf P, Roeder-Wanner U. Clobazam for refractory focal epilepsy. A controlled trial. Arch Neurol 1986;43(8):824–6.
11. Conry JA, Ng YT, Paolicchi JM, Kernitsky L, Mitchell WG, Ritter FJ, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009;50(5):1158–66.
12. Mehndiratta MM, Krishnamurthy M, Rajesh KN, Singh G. Clobazam monotherapy in drug naïve adult patients with epilepsy. Seizure 2003;12(4):226–8.
13. Jennesson M, van Eeghen AM, Caruso PA, Paolini JL, Thiele EA. Clobazam therapy of refractory epilepsy in tuberous sclerosis complex. Epilepsy Res 2013;104(3):269–74.
14. Koeppen D, Baruzzi A, Capozza M, Chauvel P, Courjon J, Favel P, et al. Clobazam in therapy-resistant patients with partial epilepsy: a double-blind placebo-controlled crossover study. Epilepsia 1987;28(5):495–506.
15. Möhler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002;300(1):2–8.
16. Hanks GW. Clobazam: pharmacological and therapeutic profile. Br J Clin Pharmacol 1979;7(Suppl 1):151S–155S.
17. Giarratano M, Standley K, Benbadis SR. Clobazam for treatment of epilepsy. Expert Opin Pharmacother 2012;13(2):227–33.
18. Fielding S, Hoffmann I. Pharmacology of anti-anxiety drugs with special reference to clobazam. Br J Clin Pharmacol 1979;7(Suppl 1):7S–15S.
19. Ng YT, Collins SD. Clobazam. Neurotherapeutics 2007;4(1):138– 44.
20. Singh A, Guberman AH, Boisvert D. Clobazam in long-term epilepsy treatment: sustained responders versus those developing tolerance. Epilepsia 1995;36(8):798–803.
21. Ekici A, Ozdemir O, Yimenicioglu S, Oren A, Sen I. Hot Water Epilepsy Successfully Treated With Daily Clobazam. Pediatr Emerg Care 2017;33(10):e98–e99.
22. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51(6):1069–77.
23. Abou-Khalil BW. Antiepileptic Drugs. Continuum (Minneap Minn) 2016;22(1 Epilepsy):132–56.
24. Kaushal S, Rani A, Chopra SC, Singh G. Safety and efficacy of clobazam versus phenytoin-sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. Neurol India 2006;54(2):157–60.
25. Andrade R, García-Espinosa A, Machado-Rojas A, GarcíaGonzález ME, Trápaga-Quincoses O, Morales-Chacón LM. A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy. Rev Neurol 2009;49(11):581–6.
26. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. Epilepsia 1998;39(9):952–9.

APA	Sirin N, Baykan B (2020). Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center. , 155 - 160.
Chicago	Sirin Nermin Gorkem,Baykan Betul Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center. (2020): 155 - 160.
MLA	Sirin Nermin Gorkem,Baykan Betul Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center. , 2020, ss.155 - 160.
AMA	Sirin N,Baykan B Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center. . 2020; 155 - 160.
Vancouver	Sirin N,Baykan B Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center. . 2020; 155 - 160.
IEEE	Sirin N,Baykan B "Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center." , ss.155 - 160, 2020.
ISNAD	Sirin, Nermin Gorkem - Baykan, Betul. "Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center". (2020), 155-160.

APA	Sirin N, Baykan B (2020). Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center. Epilepsi, 26(3), 155 - 160.
Chicago	Sirin Nermin Gorkem,Baykan Betul Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center. Epilepsi 26, no.3 (2020): 155 - 160.
MLA	Sirin Nermin Gorkem,Baykan Betul Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center. Epilepsi, vol.26, no.3, 2020, ss.155 - 160.
AMA	Sirin N,Baykan B Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center. Epilepsi. 2020; 26(3): 155 - 160.
Vancouver	Sirin N,Baykan B Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center. Epilepsi. 2020; 26(3): 155 - 160.
IEEE	Sirin N,Baykan B "Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center." Epilepsi, 26, ss.155 - 160, 2020.
ISNAD	Sirin, Nermin Gorkem - Baykan, Betul. "Clobazam as an Add-on Therapy of Patients with Drug-resistant Epilepsy: Experience of a Tertiary Epilepsy Center". Epilepsi 26/3 (2020), 155-160.